Celyad SA

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. 1.71%30.2614.1%$178.05m
AMRNAmarin Corp. Plc -0.75%19.911.7%$159.55m
AXSMAxsome Therapeutics, Inc. -2.31%90.341.9%$129.63m
SAVACassava Sciences, Inc. -4.40%8.250.0%$91.12m
ARQLArQule, Inc. 0.15%20.000.6%$78.96m
BHCBausch Health Cos., Inc. 1.71%30.260.0%$74.96m
SAGESAGE Therapeutics, Inc. 3.12%76.408.6%$70.78m
GWPHGW Pharmaceuticals Plc -0.13%118.976.2%$70.43m
JAZZJazz Pharmaceuticals Plc -0.36%151.052.3%$67.88m
ICPTIntercept Pharmaceuticals, Inc. -3.76%106.1116.9%$63.50m
PRGOPerrigo Co. Plc -0.82%59.026.8%$58.61m
HZNPHorizon Therapeutics Plc 0.29%38.406.6%$57.70m
ENDPEndo International Plc -2.27%6.048.8%$42.46m
ICLRICON plc 0.38%175.784.2%$41.39m
CTLTCatalent, Inc. -1.03%60.842.4%$37.19m

Company Profile

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.